TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: ANUHPHR · data 2026-11-03
Anuh Pharma Limited
In plain words
Price: 15.0% below its 52-week high of ₹99.5.
Delivery: 53.0% of traded shares were kept for delivery over the last 10 sessions, against 58.5% over the last 60.
Latest results: a net profit of ₹11 cr for the quarter ended Sept 2026 (+47.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹779 cr |
| Net profit (last 12 months) | ₹44 cr |
| Sales growth, 3 years (yearly) | 13.5% |
| Profit growth, 3 years (yearly) | 4.3% |
At a glance
Promoters 71.8% (unchanged in a year), pledged 0.0%, institutions 0.1%.
P/E 15.2, dividend yield 1.7%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.1%, ROCE 17.0%, operating margin 6.9%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 4.3% and sales growth 13.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
ANUHPHR Q2 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹185.24 crore, down 0.3% YoY and down 4.4% QoQ.
Net profit was ₹11.21 crore, up 47.3% YoY and down 1.8% QoQ.
Operating margin was 9.1% (6.4% a year ago).
EPS was ₹1.12, up 47.4% YoY and down 1.8% QoQ.
ANUHPHR के Q2 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹185.24 करोड़; पिछले साल की तुलना में 0.3% की गिरावट, पिछली तिमाही की तुलना में 4.4% की गिरावट।
शुद्ध मुनाफ़ा: ₹11.21 करोड़; पिछले साल की तुलना में 47.3% की बढ़त, पिछली तिमाही की तुलना में 1.8% की गिरावट।
ऑपरेटिंग मार्जिन: 9.1% (एक साल पहले 6.4%)।
EPS: ₹1.12; पिछले साल की तुलना में 47.4% की बढ़त, पिछली तिमाही की तुलना में 1.8% की गिरावट।
ANUHPHRના Q2 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹185.24 કરોડ; ગયા વર્ષની સરખામણીએ 0.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 4.4% ઘટાડો.
ચોખ્ખો નફો: ₹11.21 કરોડ; ગયા વર્ષની સરખામણીએ 47.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.8% ઘટાડો.
ઓપરેટિંગ માર્જિન: 9.1% (એક વર્ષ પહેલાં 6.4%).
EPS: ₹1.12; ગયા વર્ષની સરખામણીએ 47.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.8% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 0/30: Delivery 44.7% over the last 20 sessions vs 49.0% in the 40 before (0.91x); shares delivered per day 0.54x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend ● Bonus
- 30 Oct 26Results Q2 FY27 results: profit +47.3% YoY +6.0% next session
- 7 Aug 26Results Q1 FY27 results: profit +37.6% YoY -2.1% next session
- 5 Aug 26Dividend Dividend ₹1.5 (ex-date) -1.3% next session
- 20 May 26Results Q4 FY26 results: profit −6.3% YoY -4.5% next session
- 6 Feb 26Results Q3 FY26 results: profit +30.1% YoY +3.9% next session
- 26 Nov 25Results Q2 FY26 results: net profit ₹7.6 cr -0.5% next session
- 14 Aug 25Dividend Dividend ₹1.5 (ex-date) -1.5% next session
- 8 Aug 25Results Q1 FY26 results: net profit ₹8.3 cr -2.5% next session
- 15 Jul 25Bonus Bonus 1:1 (ex-date) -1.4% next session
- 24 May 25Results Q4 FY25 results: net profit ₹12.5 cr -1.1% next session
- 7 Feb 25Results Q3 FY25 results: net profit ₹10.3 cr -9.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹185 cr | ₹11 cr | +47.3% | 9.1% | 1.12 |
| Jun 2026 | ₹194 cr | ₹11 cr | +37.6% | 8.4% | 1.14 |
| Mar 2026 | ₹202 cr | ₹12 cr | -6.3% | 9.8% | 1.17 |
| Dec 2025 | ₹197 cr | ₹13 cr | +30.1% | 8.5% | 1.34 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 71.80% | 71.80% | 71.80% | 71.82% |
| Foreign institutions (FII) | 0.11% | 0.01% | 0.05% | 0.00% |
| Domestic institutions (DII) | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 16.80% | 16.89% | 17.03% | 17.15% |
| Number of shareholders | 28,447 | 27,484 | 27,425 | 27,889 |
Common questions
What was Anuh Pharma Limited's latest quarterly profit?
Anuh Pharma Limited reported a net profit of ₹11 cr for the quarter ended Sept 2026 (+47.3% on the same quarter a year earlier), on revenue of ₹185 cr.
How much do promoters hold in Anuh Pharma Limited?
Promoters held 71.80% of Anuh Pharma Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Anuh Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Anuh Pharma Limited's P/E ratio?
About 15.2, based on the last 12 months' earnings and a price of ₹84.56 (data 2026-11-03).
What is the 52-week high and low of Anuh Pharma Limited?
The 52-week high is ₹99.5 and the 52-week low is ₹67.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Anuh Pharma Limited | ₹84.56 | ₹873 cr | 15.2 | — | 12.1% | 17% | 0 | -4.1% |
| Lincoln Pharmaceuticals Ltd | ₹512.2 | ₹1,005 cr | 10.6 | — | 12.3% | 10.9% | 0.01 | -3.7% |
| Remus Pharmaceuticals Ltd. | ₹831 | ₹994 cr | 26.5 | 2.8 | 12.2% | 14.7% | 0.08 | +22.5% |
| Sudarshan Pharma Industries Ltd | ₹35.16 | ₹895 cr | 30 | 4.6 | 16.3% | 28.8% | 1.84 | +4.0% |
| Themis Medicare Limited | ₹100.88 | ₹875 cr | 23.3 | — | 0.3% | -2.3% | 0.25 | -19.4% |
| Shree Ganesh Remedies Ltd. | ₹598.85 | ₹792 cr | 49.8 | — | 11.5% | 14.4% | 0.19 | +21.0% |
Compare ANUHPHR with LINCOLN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ANUHPHR in TickerKhoj →